Pharmacist Moms Group™

Ming-Hei Tai, PharmD, BCOP, shares his concerns about the AQUILA trial and use of daratumumab for smoldering multiple myeloma.

Donna Ryan discusses the landscape of GLP-1 medications and the lineup of indications that the drug class has received indications for in recent years.

Edward Kim, MD, MBA, discusses critical points of patient leakage in precision medicine, emphasizing the role of multidisciplinary teams in streamlining care, managing medications, and improving patient outcomes.

Edward Kim, MD, MBA, highlights the challenges of patient disengagement, data fragmentation, and provider education in precision medicine, emphasizing the need for personalized approaches to enhance patient outcomes, particularly in oncology.

Christian Ruff explains the strong efficacy associated with abelacimab compared with rivaroxaban in the AZALEA-TIMI 71 trial.

Panelists discuss how recent FDA regulatory actions regarding obeticholic acid have raised concerns about its long-term safety profile and accessibility, leading health care teams to develop strategies for supporting patients through treatment transitions while navigating insurance coverage and access challenges for newer primary biliary cholangitis (PBC) therapies.

Tocilizumab-anoh is expected to increase competition, improve patient access, and deliver cost savings in the treatment of various inflammatory conditions.

Three experts from UPMC Health Plan highlight the importance of treating patients’ physical, mental, and social health when managing diabetes, rather than the disease alone.

Naga Vara Kishore Pillarsetty, PhD, discusses advancements in radiopharmaceuticals for cancer therapy, noting common supply chain challenges, radiation safety measures, and patient misconceptions with the use of these drugs.